FTC rules Impax received illegal payments to block pain reliever generic
01-04-2019
FTC approves Amneal’s $1.45bn acquisition of Impax
11-07-2018
Amneal and Impax merge to become ‘fifth largest’ generics company
19-10-2017
designer491 / iStockphoto.com
The Federal Trade Commission (FTC) is requiring Impax to divest rights and assets for ten products, as part of a settlement resolving charges that Amneal’s $1.45 billion acquisition would be anti-competitive.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
FTC, Federal Trade Commission, generics, Amneal Pharmaceuticals, Impax Laboratories, mergers and acquisitions, M&S, anticompetitive
